Minerva Neurosciences (NERV) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Minerva Neurosciences (NERV) is Moderate Underperform.

The composite score behind that read is -0.21, weighing +0.06 of bullish evidence against -0.39 bearish.

Minerva Neurosciences last closed at $3.18, -1.24% on the session.

Against the IVW growth benchmark the position is -2.04% over the forecast window.

The read is built from 15 underlying insights — 1 bullish and 14 bearish.

Agreement across those insights is 93%.

20 graded predictions for NERV so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Minerva Neurosciences in the 98th percentile on return on equity, where 100 is best.

Minerva Neurosciences is classified under Health Care / Biotechnology, with a market capitalisation of $153.75M.

StockMap tracks Minerva Neurosciences as the 263rd largest of the 381 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 301 Neutral, 63 Moderate Underperform and 17 Moderate Outperform.

On that composite Minerva Neurosciences ranks 331st of 381 in the group, against a group median of -0.08.